WO2007146024A3 - Cytomegalovirus surface protein complex for use in vaccines and as a drug target - Google Patents

Cytomegalovirus surface protein complex for use in vaccines and as a drug target Download PDF

Info

Publication number
WO2007146024A3
WO2007146024A3 PCT/US2007/013365 US2007013365W WO2007146024A3 WO 2007146024 A3 WO2007146024 A3 WO 2007146024A3 US 2007013365 W US2007013365 W US 2007013365W WO 2007146024 A3 WO2007146024 A3 WO 2007146024A3
Authority
WO
WIPO (PCT)
Prior art keywords
cmv
protein complex
vaccines
methods
pul130
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/013365
Other languages
French (fr)
Other versions
WO2007146024A2 (en
Inventor
Thomas Shenk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Princeton University
Original Assignee
Princeton University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38832360&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2007146024(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Princeton University filed Critical Princeton University
Priority to CA002654563A priority Critical patent/CA2654563A1/en
Priority to EP16152758.5A priority patent/EP3031469B1/en
Priority to JP2009514365A priority patent/JP5822433B2/en
Priority to EP07777421.4A priority patent/EP2037959B1/en
Publication of WO2007146024A2 publication Critical patent/WO2007146024A2/en
Publication of WO2007146024A3 publication Critical patent/WO2007146024A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit human CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection.
PCT/US2007/013365 2006-06-07 2007-06-06 Cytomegalovirus surface protein complex for use in vaccines and as a drug target Ceased WO2007146024A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002654563A CA2654563A1 (en) 2006-06-07 2007-06-06 Cytomegalovirus surface protein complex for use in vaccines and as a drug target
EP16152758.5A EP3031469B1 (en) 2006-06-07 2007-06-06 Cytomegalovirus surface protein complex for use in vaccines and as a drug target
JP2009514365A JP5822433B2 (en) 2006-06-07 2007-06-06 Cytomegalovirus surface protein complex for use as a drug target in a vaccine
EP07777421.4A EP2037959B1 (en) 2006-06-07 2007-06-06 Cytomegalovirus surface protein complex for use in vaccines and as a drug target

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US81168906P 2006-06-07 2006-06-07
US60/811,689 2006-06-07
US90254407P 2007-02-20 2007-02-20
US60/902,544 2007-02-20

Publications (2)

Publication Number Publication Date
WO2007146024A2 WO2007146024A2 (en) 2007-12-21
WO2007146024A3 true WO2007146024A3 (en) 2008-03-20

Family

ID=38832360

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/013365 Ceased WO2007146024A2 (en) 2006-06-07 2007-06-06 Cytomegalovirus surface protein complex for use in vaccines and as a drug target

Country Status (5)

Country Link
US (5) US7704510B2 (en)
EP (2) EP3031469B1 (en)
JP (3) JP5822433B2 (en)
CA (1) CA2654563A1 (en)
WO (1) WO2007146024A2 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3031469B1 (en) 2006-06-07 2023-08-23 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
CA2682700A1 (en) * 2007-05-11 2008-11-20 Vakzine Projekt Management Gmbh Composition containing hcmv particles
US9439960B2 (en) 2007-10-10 2016-09-13 The Trustees Of Princeton University Cytomegalovirus vaccines and methods of production
AU2009223688B2 (en) * 2008-03-10 2014-12-11 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
AU2013202396B2 (en) * 2008-07-16 2014-07-10 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
PE20141435A1 (en) 2008-07-16 2014-10-22 Inst Research In Biomedicine NEUTRALIZING ANTIBODIES OF HUMAN CYTOMEGALOVIRUS
AU2012203417B2 (en) * 2008-07-16 2014-07-10 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
EP2303923B1 (en) * 2008-07-16 2015-06-24 Institute for Research in Biomedicine Human cytomegalovirus neutralising antibodies and use thereof
US8580276B2 (en) 2009-06-05 2013-11-12 City Of Hope Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
WO2011057124A1 (en) * 2009-11-06 2011-05-12 Transtarget, Inc. Polyclonal bispecific antibody compositions and method of use
WO2011076883A1 (en) 2009-12-23 2011-06-30 4-Antibody Ag Binding members for human cytomegalovirus
HUE047796T2 (en) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa Introduction of RNA to activate multiple immune pathways
HUE026646T2 (en) 2010-07-06 2016-07-28 Glaxosmithkline Biologicals Sa Liposomes with lipids having an advantageous pka-value for rna delivery
PL2591114T3 (en) 2010-07-06 2017-08-31 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of rna
PT3970742T (en) 2010-08-31 2022-06-27 Glaxosmithkline Biologicals Sa Pegylated liposomes for delivery of immunogen-encoding rna
US20130164289A1 (en) * 2010-09-09 2013-06-27 Virginia Commonwealth University Human cytomegalovirus vaccine
WO2012047732A2 (en) * 2010-09-29 2012-04-12 Genentech, Inc. Antibody compositions and methods of use
JP2013544504A (en) * 2010-10-11 2013-12-19 ノバルティス アーゲー Antigen delivery platform
CA2825825A1 (en) * 2011-01-27 2012-08-02 The Trustees Of Princeton University Inhibitors of mtor kinase as anti-viral agents
WO2013006838A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
TWI570240B (en) * 2011-09-09 2017-02-11 默沙東公司 Conditional replication CMV as a cellular giant virus vaccine
WO2013054199A2 (en) * 2011-10-12 2013-04-18 Novartis Ag Cmv antigens and uses thereof
KR20140138971A (en) * 2012-03-28 2014-12-04 제넨테크, 인크. Anti-hcmv idiotypic antibodies and uses thereof
ES2753138T3 (en) 2012-07-06 2020-04-07 Glaxosmithkline Biologicals Sa Cytomegalovirus protein complexes
DK2877580T3 (en) 2012-07-27 2019-04-23 Hope City VAT VACCINE TO DELIVER A UL128 COMPLEX AND PREVENT CMV INFECTION
EP2943221A1 (en) * 2013-01-10 2015-11-18 Novartis AG Influenza virus immunogenic compositions and uses thereof
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
US20150322115A1 (en) * 2014-05-08 2015-11-12 Redvax Gmbh Means and methods for treating cmv
EP3015475A1 (en) 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens
EP3048114A1 (en) 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE CYTOMEGALOVIRUS HUMAN
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
MA46584A (en) 2016-10-21 2019-08-28 Modernatx Inc HUMAN CYTOMEGALOVIRUS VACCINE
US11572389B2 (en) * 2017-01-27 2023-02-07 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccine compositions of herpesvirus envelope protein combinations to induce immune response
CA3060019A1 (en) 2017-04-19 2018-10-25 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
KR20250006307A (en) * 2017-09-13 2025-01-10 사노피 파스퇴르 Human cytomegalovirus immunogenic composition
CN112512569A (en) 2018-05-11 2021-03-16 希望之城 MVA vectors expressing multiple Cytomegalovirus (CMV) antigens and uses thereof
CA3116175A1 (en) 2018-10-17 2020-04-23 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
WO2020208082A1 (en) * 2019-04-09 2020-10-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating cmv related diseases
KR102837045B1 (en) 2020-06-09 2025-07-23 케이엠 바이올로직스 가부시키가이샤 Fusion protein of pentamer and gb of cytomegalovirus, and vaccine containing said fusion protein
TWI810589B (en) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 Human cytomegalovirus gb polypeptide
US20230293673A1 (en) * 2020-08-06 2023-09-21 La Jolla Institute For Immunology Methods for treating and preventing cytomegalovirus infection
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
TWI843471B (en) * 2022-03-11 2024-05-21 財團法人國家衛生研究院 Composition comprising antigen and dna and use thereof
WO2025231404A1 (en) * 2024-05-03 2025-11-06 The Trustees Of Princeton University Telomerase inhibition for treating or inhibiting herpesvirus infections

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066629A2 (en) * 2001-02-21 2002-08-29 Gabriele Hahn Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates
US20040110188A1 (en) * 2002-07-16 2004-06-10 Gabriele Hahn Novel virus encoded chemokines determine the tissue tropism of human cytomegalovirus (HCMV)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267965B1 (en) * 1981-12-24 2001-07-31 Virogenetics Corporation Recombinant poxvirus—cytomegalovirus compositions and uses
EP3031469B1 (en) * 2006-06-07 2023-08-23 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
GB0700133D0 (en) * 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066629A2 (en) * 2001-02-21 2002-08-29 Gabriele Hahn Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates
US20040110188A1 (en) * 2002-07-16 2004-06-10 Gabriele Hahn Novel virus encoded chemokines determine the tissue tropism of human cytomegalovirus (HCMV)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG DAI ET AL: "Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 102, no. 50, December 2005 (2005-12-01), pages 18153 - 18158, XP002463457, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
EP2037959B1 (en) 2016-01-27
JP5822433B2 (en) 2015-11-24
JP2013241442A (en) 2013-12-05
EP3031469B1 (en) 2023-08-23
WO2007146024A2 (en) 2007-12-21
US7704510B2 (en) 2010-04-27
EP2037959A2 (en) 2009-03-25
US20140370026A1 (en) 2014-12-18
US20190358317A1 (en) 2019-11-28
CA2654563A1 (en) 2007-12-21
US8828399B2 (en) 2014-09-09
US20120226023A1 (en) 2012-09-06
EP3031469A1 (en) 2016-06-15
JP2016128418A (en) 2016-07-14
US11129891B2 (en) 2021-09-28
JP2009539845A (en) 2009-11-19
US20080187545A1 (en) 2008-08-07
JP6274770B2 (en) 2018-02-07
US20110200633A1 (en) 2011-08-18
US8173362B2 (en) 2012-05-08

Similar Documents

Publication Publication Date Title
WO2007146024A3 (en) Cytomegalovirus surface protein complex for use in vaccines and as a drug target
WO2008083239A3 (en) Compositions and methods for stimulating an immune response
WO2012075040A3 (en) mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
WO2008039874A3 (en) Cancer stem cell antigen vaccines and methods
WO2008083174A3 (en) Compositions and methods for the treatment of infections and tumors
WO2006040357A3 (en) Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
WO2009131730A3 (en) IMMUNOGENIC COMPOSITIONS FOR ACTIVATING γδ T CELLS
WO2011133960A3 (en) Lysosomal storage disease enzyme
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
WO2007109370A3 (en) Methods for identifying polypeptide targets and uses thereof for treating immunological diseases
WO2006103562A3 (en) Endogenous retrovirus and proteins encoded by env gene as a target for cancer treatment
WO2017203370A3 (en) Cmv epitopes
WO2010031749A9 (en) Compositions and methods for detecting tlr3
WO2004030696A3 (en) Composition for vaccination
WO2006078284A3 (en) Methods and compositions related to antiviral therapy using algae and cyanobacteria
WO2011126856A3 (en) Herpes simplex virus mutant icp0
WO2004071430A3 (en) RNAi TARGETING OF VIRUSES
WO2004087766A3 (en) Peptabody for cancer treatment
WO2012059725A8 (en) Peg or peg block copolymers for treating colorectal cancer
WO2007081896A3 (en) Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
WO2000057909A3 (en) Attenuated dengue-2 virus vaccine
WO2006023598A3 (en) Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
WO2006137938A3 (en) Antibody fragments for protection from pathogen infection and methods of use thereof
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna
WO2000057904A3 (en) Attenuated dengue-3 virus vaccine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07777421

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2654563

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009514365

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2007777421

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU